Skip to main content

LMR Partners LLP

Position in NBIX — Neurocrine Biosciences Inc

CIK 1578621 LONDON, X0

Position in NBIX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$7,317,497
+$1,816,895 QoQ
Shares Held
55,545
+16.3% QoQ
Ownership
0.055%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Sep 2022
10 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in NBIX Over Time

Shares Held

Position Value (USD)

Derivatives in NBIX

reported options exposure · as of Sep 30, 2024
CallValue
$15,370,348
CallShares
133,400
PutValue
$8,146,054
PutShares
70,700

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

LMR Partners LLP holds $45,048,985 across 4 Drug Manufacturers - Specialty & Generic names. NBIX ranks #3 (16.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
3 NBIX
Neurocrine Biosciences Inc
This page
55,545 $7,317,497

All Filings in NBIX

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $7,317,497 55,545
2024-09-30 $15,370,348 133,400
2024-09-30 $8,146,054 70,700
2024-09-30 $5,500,602 47,740
2024-06-30 $10,696,959 77,700
2024-06-30 $29,158,506 211,800
2024-03-31 $22,274,080 161,500
2024-03-31 $2,634,272 19,100
2023-12-31 $382,762 2,905
2023-09-30 $326,812 2,905
2023-06-30 $273,941 2,905
2023-03-31 $294,044 2,905
2022-12-31 $346,973 2,905
2022-09-30 $531,050 5,000